• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Viking Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    7/23/25 4:05:34 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VKTX alert in real time by email
    8-K
    0001607678false00016076782025-07-232025-07-23

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 23, 2025

     

     

    Viking Therapeutics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-37355

    46-1073877

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    9920 Pacific Heights Blvd, Suite 350

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 858 704-4660

     

    Viking Therapeutics, Inc.

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.00001 per share

     

    VKTX

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    In this report, “Viking Therapeutics,” “Viking,” “Company,” “we,” “us” and “our” refer to Viking Therapeutics, Inc.

    Item 2.02 Results of Operations and Financial Condition.

    On July 23, 2025, we issued a press release reporting our financial results for the second quarter ended June 30, 2025 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

    In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No

     

    Description

    99.1

     

    Press release issued July 23, 2025, reporting financial results for the second quarter ended June 30, 2025 and providing a corporate update.

    104

     

    Cover Page Interactive Data File (embedded with the Inline XBRL document)

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Viking Therapeutics, Inc.

     

     

     

     

    Date:

    July 23, 2025

    By:

    /s/ Brian Lian, Ph.D.

     

     

     

    Brian Lian, Ph.D.
    President and Chief Executive Officer
    (Principal Executive Officer)

     


    Get the next $VKTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VKTX

    DatePrice TargetRatingAnalyst
    4/29/2025$104.00Overweight
    Cantor Fitzgerald
    4/8/2025$30.00Neutral
    Goldman
    2/13/2025$102.00Sector Outperform
    Scotiabank
    2/7/2025$38.00Neutral
    Citigroup
    12/2/2024Overweight
    Piper Sandler
    11/22/2024$109.00Buy
    B. Riley Securities
    11/4/2024$90.00 → $102.00Buy
    H.C. Wainwright
    9/11/2024$80.00Overweight
    JP Morgan
    More analyst ratings

    $VKTX
    SEC Filings

    View All

    Viking Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Viking Therapeutics, Inc. (0001607678) (Filer)

    8/19/25 7:09:43 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.

    SCHEDULE 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    8/6/25 12:19:41 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Viking Therapeutics Inc.

    10-Q - Viking Therapeutics, Inc. (0001607678) (Filer)

    7/23/25 5:01:26 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

    Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 99% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmac

    8/19/25 7:08:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in ObesityPhase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25Continued Progress with Amylin Program; IND Planned 4Q25Strong Quarter-End Cash Position of $808 MillionSAN DIEGO, July 23, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2025, and provided an update on its clinical pipeline and other corporate developm

    7/23/25 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

     Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time           SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2025 after the market close on Wednesday, July 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or

    7/16/25 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Viking Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $104.00

    4/29/25 8:13:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Viking Therapeutics with a new price target

    Goldman initiated coverage of Viking Therapeutics with a rating of Neutral and set a new price target of $30.00

    4/8/25 9:33:02 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Viking Therapeutics with a new price target

    Scotiabank initiated coverage of Viking Therapeutics with a rating of Sector Outperform and set a new price target of $102.00

    2/13/25 8:13:09 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

    4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)

    4/8/25 7:05:30 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    4/2/25 6:29:36 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Zante Greg was granted 7,667 shares and sold $118,428 worth of shares (4,266 units at $27.76), increasing direct ownership by 2% to 168,660 units (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    7/3/25 3:31:07 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Lian Brian was granted 48,333 shares and sold $747,633 worth of shares (26,889 units at $27.80), increasing direct ownership by 0.91% to 2,388,014 units (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    7/3/25 3:31:13 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Mancini Marianna sold $118,473 worth of shares (4,266 units at $27.77) and was granted 7,667 shares, increasing direct ownership by 0.91% to 377,535 units (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    7/3/25 3:30:32 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Financials

    Live finance-specific insights

    View All

    Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

    Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 99% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmac

    8/19/25 7:08:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in ObesityPhase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25Continued Progress with Amylin Program; IND Planned 4Q25Strong Quarter-End Cash Position of $808 MillionSAN DIEGO, July 23, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2025, and provided an update on its clinical pipeline and other corporate developm

    7/23/25 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

     Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time           SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2025 after the market close on Wednesday, July 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or

    7/16/25 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/12/24 5:54:36 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/4/24 1:54:45 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care